cagrilintide semaglutide combination cagrisema phase 3 2025 in Adults With or Without Diabetes – REDEFINE 1 & 2 • 💊 2.4 mg + 2.4 mg once weekly • 📉 –20.4% weight loss (non-diabetic) & –13.7% (T2D) CagriSema Reduces Blood Pressure in

Its now approved as a weight loss treatment due to its powerful effect on hunger and satiety (the feeling of fullness)

If needed to achieve glycemic goals, use of anti-diabetic agents showing potential CV benefits (e.g., metformin, pioglitazone) or proven CV safety (e.g., DPP-4 inhibitors, lixisenatide, exenatide, insulin, glimepiride) with lower risks of hypoglycemia is recommended [49]

Your provider assesses these contraindications and medical history before establishing your personal titration plan

Contact Tri-County Longevity Center to schedule your personalized consultation

No pharmacy visit required

Nat Rev Gastroenterol Hepatol 2020;17:223-37